807 Combination therapy with cytostatic drugs and a polyenzyme preparation decreases concentration of soluble tumor necrosis factor receptors P55 and P75 in serum of patients with multiple myeloma

• Published in: European journal of cancer (1990) 1995-11, Vol.31, p.S169-S169
• Main Authors: Desser, L., Sakalova, A., Zavadova, E., Holomanova, T., Mohr, T.
• Format: Article
• Language: English
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/0959-8049(95)96056-J

Conventional chemotherapy with drug combinations is still the preferred treatment for multiple myeloma. Immuno-chemotherapy with Wobe-Mugos (a polyenzyme preparation) and MOCCA/VMPC of MM patients results in a prolongation ofclinical remission and a significant prolongation of survival time in comparison to MM patients who received chemotherapy only (Sakalova and Stauder et al. in prep.). In the present study we measured the serum levels of β2 microglobulin ( β2M) and of soluble tumor necrosis factor receptors (sTNF-R: p55 and p75) in serum of 169 patients to determine their value as a monitor of diseases status in untreated, chemotherapy treated and immunochemotherapy treated MM patients. Serum levels of p55 and p75 as well as β2M were elevated in parallel with the clinical stage in untreated patients. sTNF-R and β2 M correlate ( β2m/p55: 0.7162 P < 0.0001; β2M/p75: 0.7221 P < 0.000l—Spearman correlation coefficients). The mean levels of p55 receptors (control:2339 pg/ml) were increased to 4866 ± 2067 pg/ml ( P < 0.0001 v normal) in stage II and to 8196 ± 4185 ( P < 0.0001 v normal) in stage III. The mean levels (control: 3542 pg/ml) of p75 were increased to 6248 ± 2278 ( P < 0.0001 v normal) in stage II and to 13873 ± 6229 ( P < 0.0001 v control) in stage III. Immuno-chemotherapy significantly reduced serum levels of p55, p75 and β2M in stages I and II in comparison to chemotherapy alone (p55: 2970 ± 1095 P < 0.01 v. chemotherapy p75: ± 4345 ± 1497 P < 0.05 v. chemotherapy—stage II). In stage III the serum concentrations of p55 and p75 were reduced by chemotherapy (p55: P < 0.05; p75: P < 0.02 v. untreated stage III) but to a higher degree by Immuno-chemotherapy (p55: P < 0.001; p75: P < 0.0001 v. untreated stage III). Our results suggest that p55 and p75 concentrations in serum of MM patients correlate well with β2M and may be potential markers for both disease progression and response to therapy.